Evaluation of new endothelin receptor antagonist macitentan pharmacological properties for the treatment of pulmonary arterial hypertension
AbstractArticle presents the main results of SERAPHIN study [effect of new endothelin receptor antagonist macitentan on patients with pulmonary arterial hypertension (PAH)]. The obtained findings confirm high efficiency of macitentan and good tolerance to the drug for patients with PAH.
Keywords:pulmonary hypertension, macitentan